These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 19335070)

  • 1. Wnt signaling as a therapeutic target for bone diseases.
    Hoeppner LH; Secreto FJ; Westendorf JJ
    Expert Opin Ther Targets; 2009 Apr; 13(4):485-96. PubMed ID: 19335070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton.
    Baron R; Rawadi G
    Endocrinology; 2007 Jun; 148(6):2635-43. PubMed ID: 17395698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Wnt signaling and glucocorticoid-induced osteoporosis].
    Ohnaka K
    Clin Calcium; 2006 Nov; 16(11):1812-6. PubMed ID: 17079847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heavy Metal Ion Regulation of Gene Expression: MECHANISMS BY WHICH LEAD INHIBITS OSTEOBLASTIC BONE-FORMING ACTIVITY THROUGH MODULATION OF THE Wnt/β-CATENIN SIGNALING PATHWAY.
    Beier EE; Sheu TJ; Dang D; Holz JD; Ubayawardena R; Babij P; Puzas JE
    J Biol Chem; 2015 Jul; 290(29):18216-18226. PubMed ID: 25975268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wnt signaling and osteoblastogenesis.
    Bodine PV; Komm BS
    Rev Endocr Metab Disord; 2006 Jun; 7(1-2):33-9. PubMed ID: 16960757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the Wnt signaling pathway in osteoblast commitment and differentiation.
    Yavropoulou MP; Yovos JG
    Hormones (Athens); 2007; 6(4):279-94. PubMed ID: 18055419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
    Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
    J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization.
    Chen Y; Hu Y; Lu K; Flannery JG; Ma JX
    J Biol Chem; 2007 Nov; 282(47):34420-8. PubMed ID: 17890782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesd is a universal inhibitor of Wnt coreceptors LRP5 and LRP6 and blocks Wnt/beta-catenin signaling in cancer cells.
    Lu W; Liu CC; Thottassery JV; Bu G; Li Y
    Biochemistry; 2010 Jun; 49(22):4635-43. PubMed ID: 20446724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secreted frizzled related protein 1 regulates Wnt signaling for BMP2 induced chondrocyte differentiation.
    Gaur T; Rich L; Lengner CJ; Hussain S; Trevant B; Ayers D; Stein JL; Bodine PV; Komm BS; Stein GS; Lian JB
    J Cell Physiol; 2006 Jul; 208(1):87-96. PubMed ID: 16575902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoblasts in osteoporosis: past, emerging, and future anabolic targets.
    Marie PJ; Kassem M
    Eur J Endocrinol; 2011 Jul; 165(1):1-10. PubMed ID: 21543379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular bases of the regulation of bone remodeling by the canonical Wnt signaling pathway.
    Glass DA; Karsenty G
    Curr Top Dev Biol; 2006; 73():43-84. PubMed ID: 16782455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo analysis of Wnt signaling in bone.
    Glass DA; Karsenty G
    Endocrinology; 2007 Jun; 148(6):2630-4. PubMed ID: 17395705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The promise of canonical Wnt signaling modulators in enhancing bone repair.
    Gregory CA; Green A; Lee N; Rao A; Gunn W
    Drug News Perspect; 2006 Oct; 19(8):445-52. PubMed ID: 17160144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases.
    Ke HZ; Richards WG; Li X; Ominsky MS
    Endocr Rev; 2012 Oct; 33(5):747-83. PubMed ID: 22723594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum extracellular secreted antagonists of the canonical Wnt/β-catenin signaling pathway in patients with Cushing's syndrome.
    Belaya ZE; Rozhinskaya LY; Melnichenko GA; Solodovnikov AG; Dragunova NV; Iljin AV; Dzeranova LK; Dedov II
    Osteoporos Int; 2013 Aug; 24(8):2191-9. PubMed ID: 23358608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wnt signaling control of bone cell apoptosis.
    Bodine PV
    Cell Res; 2008 Feb; 18(2):248-53. PubMed ID: 18212734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.
    Semënov M; Tamai K; He X
    J Biol Chem; 2005 Jul; 280(29):26770-5. PubMed ID: 15908424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cytokines in bone diseases. Wnt signal and excessive bone formation].
    Hosoi T
    Clin Calcium; 2010 Oct; 20(10):1526-31. PubMed ID: 20890035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hormones and osteoporosis update. Mechanisms of anabolic and catabolic effects of PTH on bone].
    Kobayashi T
    Clin Calcium; 2009 Jul; 19(7):911-8. PubMed ID: 19567985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.